对比增强超声评估肝细胞癌局部治疗后治疗反应的Meta分析与系统综述
该系统综述与Meta分析纳入43篇文献(50个队列),评估CEUS在HCC局部治疗后识别残留肿瘤的诊断准确性。汇总敏感度0.85(95%CI 0.80-0.89),特异度0.94(95%CI 0.91-0.96),AUC 0.95,DOR 70.1(95%CI 62.2-148),诊断准确率93.5%。亚组分析显示不同治疗方式、残留标准、随访时机及参考标准间无显著差异。
要点
- CEUS对HCC局部治疗后残留肿瘤诊断准确率高,敏感度0.85、特异度0.94。
- TACE与消融、不同残留增强标准及随访时机间诊断性能无显著差异。
- CEUS可作为评估HCC局部治疗后残留肿瘤的可靠影像方法。
核心结论
- CEUS是识别HCC经TACE或经皮消融后残留肿瘤的高准确度方法,汇总敏感度0.85、特异度0.94、AUC 0.95。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Scopus和Cochrane图书馆至2021年3月8日,最终纳入43篇文献共50个队列。
- 纳入比较CEUS与参考标准识别HCC局部治疗后残留肿瘤的诊断准确性研究,采用双变量随机效应模型汇总敏感度、特异度、准确率和DOR。
诊断标准与关键数值
- CEUS检测残留病的汇总敏感度为0.85(95%CI 0.80-0.89),汇总特异度为0.94(95%CI 0.91-0.96)。
- 诊断准确率为93.5%,DOR为70.1(95%CI 62.2-148),AUROC为0.95。
- 亚组分析显示TACE与消融、残留增强定义标准、CEUS随访时机、研究设计及参考标准类型间诊断性能无显著差异。
临床应用与阅片要点
- CEUS可用于HCC局部治疗后随访,识别残留肿瘤具有较高敏感度和特异度。
- 阅片时关注治疗区是否存在异常增强作为残留肿瘤的征象,不同残留增强标准间诊断性能无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Contrast-enhanced ultrasound (CEUS) is a useful tool to assess treatment response after percutaneous ablation or transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). Here, we performed a systematic review and meta-analysis to evaluate the usefulness of CEUS in identifying residual tumor after locoregional therapy.
METHODS: PubMed, Scopus, and Cochrane library databases were searched from their inception until March 8, 2021, for diagnostic test accuracy studies comparing CEUS to a reference standard for identifying residual tumors after locoregional therapy of HCC. The pooled sensitivity, specificity, accuracy, and diagnostic odds ratio (DOR) were obtained using a bivariate random effects model. Subgroup analyses were performed by stratifying the studies based on study design, type of locoregional therapy, CEUS criteria for residual tumor, timing of CEUS follow up, and type of standard reference.
RESULTS: Two reviewers independently evaluated 1479 publications. After full-text review, 142 studies were found to be relevant, and 43 publications (50 cohorts) were finally included. The overall sensitivity of CEUS in detection of residual disease estimated from the bivariate random effects model was 0.85 (95% CI 0.80-0.89). Similarly, the overall specificity was 0.94 (95% CI 0.91-0.96). The diagnostic accuracy was 93.5%. The DOR was 70.1 (95% CI 62.2-148), and the AUROC was 0.95. Importantly, subgroup analysis showed no apparent differences in the diagnostic performance between locoregional therapy (TACE vs. ablation) and criteria used to define residual enhancement, timing of performing CEUS, study design, or type of reference standard.
CONCLUSION: CEUS is a highly accurate method to identify HCC residual tumor after TACE or percutaneous ablation.
引用
- Hai Y, Savsani E, Chong W, et al. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY). 2021. PMID: 34410432. doi:10.1007/s00261-021-03248-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。